



twelve times than that of phenylbutazone. On carrageenin-induced edema test, the anti-inflammatory activity of [II] administered *p.o.* was three times more potent than that of phenylbutazone, whereas it *s.c.* was slightly lower. This paper described the studies on the isolation and identification of [II] and on its anti-inflammatory characteristics.

## EXPERIMENTAL METHODS

### Materials

Roots of *A. continentalis* were purchased from a market, Chongno Street, Seoul. Bovine serum albumin (Cohn fraction V) and carrageenin ( $\lambda$  type) were purchased from Sigma Chemical Co. Phenylbutazone was grade of USP.

### Protein Stabilizing Activity

The protein stabilizing activity of a sample was assayed by its ability to inhibit heat denaturation of bovine serum albumin, as described previously<sup>11</sup>. An insoluble sample in water was thoroughly dissolved in 0.3N NaOH and then neutralized pH 8 to 9 with 0.3N HCl. The sample solution was serially diluted with 0.1 M phosphate-saline solution (pH 5.3). One unit of the protein stabilizing activity was defined as the amount of sample inhibiting 50% the heat denaturation of albumin. Specific activity was expressed as protein stabilizing activity units per gram of sample.

### Extraction and Isolation

Roots of *A. continentalis* (9 Kg) were continuously extracted and concentrated in an apparatus of a large scale consisting of an extractor (200 l volume) and a concentrator (50 l volume), which was recently installed in our Institute. A syrupy methanol-extract was removed to a rotary evaporator and further concentrated to dryness *in vacuo* (1.45 kg). Solvent fractionation of the methanol extract was carried out by tra-

cing the protein stabilizing activity as previously described.<sup>11</sup>

The ether-soluble acidic fraction (290 g) exhibiting the major activity was chromatographed on a silica gel column, using the elution solvent of hexane/ethylacetate/acetic acid (20:10:1) to give three fractions. (Fig. 1). Fraction 1 (201 g) showed a single spot at Rf 0.6 on TLC, and was crystallized from methanol to give (-)-pimara-8(14), 15-dien-19-oic acid [I] (colorless needles, 6 g), mp 158°,  $[\alpha]_D^{25}$ -147.5 (CHCl<sub>3</sub>). The filtrate was concentrated to dryness *in vacuo*, and the residue was crystallized from n-hexane to yield compound II (colorless plates, 19 g). mp: 176~8°C;  $[\alpha]_D^{20}$ : -101.2 (CHCl<sub>3</sub>); IR $_{\text{max}}^{\text{KBr}}$  cm<sup>-1</sup>: 3000~2500(broad), 3060, 1690, 1650, 875; MS: m/z 302 (M<sup>+</sup>, 40.6), 287 (M<sup>+</sup>-15, 29.6), 91(100); PMR  $\delta_{\text{ppm}}^{\text{TMS}}$ : 0.95(3H, s), 1.24(3H, s), 2.65 (1H, m), 4.75(2H, d, J=3Hz), 11.4(1H, br. s.); CMR  $\delta_{\text{ppm}}^{\text{TMS}}$ : 15.66 (C-20), 18.53(C-11), 19.24(C-2), 21.96(C-6), 29.01(C-18), 33.20(C-12), 37.96(C-3), 39.84 (C-14), 39.84(C-10), 40.91, 41, 48, (C-1, C-7), 43.94(C-4), 43.94(C-13), 44.37(C-8), 49.17(C-15), 55.42(C-9), 57.35(C-5), 103.21 (C-17), 155.56(C-16), 184.86(C-19).




Fig. 1. Thin layer chromatograms of ether-soluble acidic fraction and its sub-fractions on a silica gel plate. Solvent: Hexane/ethylacetate/acetic acid (20:10:1). Visualized by d-H<sub>2</sub>SO<sub>4</sub>. 1, 2, 3: Fr. 1, 2 and 3

**Methylation of [II]**

Methyl ester of [II] was obtained by treatment of diazomethane in ethyl ether and recrystallized from methanol. mp: 86~8°C; IR,  $\nu_{\text{max}}^{\text{KBr}}$   $\text{cm}^{-1}$ : 3050, 1725, 1650, 870; MS: m/z 316 ( $\text{M}^+$ , 4.7), 273(20.9) 257(44.2), 94(100); PMR  $\delta_{\text{ppm}}^{\text{MS}}$ : 0.85(3H, s), 1.18(3H, s), 2.60(1H, m), 3.62(3H, s), 4.72(2H, br. s.)

**GC/MS Analysis**

GC/MS analysis of the ether-soluble acidic fraction after treatment of diazomethane was carried out under the conditions; OV-1 fused capillary column (0.2mm i.d.  $\times$  250cm, temperature 1: 180°C, time 1: 2 min, rate: 4°C/min, temperature 2: 320°C), carrier gas: helium ( $\bar{u}$  = 20cm/sec), scanning mass range: m/z 40~600. Four main peaks were obtained. (Fig. 2)

Peak 1: m/z 270( $\text{M}^+$ , 2.9), 239(2.3), 227(4.7), 213(1.0), 199(2.0), 185(2.9), 171(2.6), 157(1.4), 143(13.5), 129(6.4), 74(100).

Peak 2: m/z 294( $\text{M}^+$ , 1.2), 263(2.0), 220(1.4), 205(0.8), 191(1.2), 178(2.4), 164(5.9), 150(8.8), 136(10.4), 135(11.4), 123(1.36), 109(25.7), 95(60.7), 81(75.6), 67(96.1), 55(100).

Peak 3: m/z 316( $\text{M}^+$ , 1.9), 301(1.2), 273(0.2), 257(7.6), 241(9.8), 216(1.9), 188(7.9), 180(18.2), 159(5.6), 121(100).

Peak 4: m/z 316( $\text{M}^+$ , 3.3), 301(2.7), 273(10.5), 257(42.3), 241(37.5), 213(20.0), 91(100).

**Instrumental Analysis**

All melting points were taken on a Mitamura heat block apparatus and given uncorrected values. A UV/visible spectrophotometer, Gilford type 2600 was used for the measurements of UV absorption spectra and the turbidity of heat denaturated albumin solution. Proton and  $^{13}\text{C}$  NMR spectra were obtained in  $\text{CDCl}_3$  solution using TMS as an internal standard on a Varian FT 80-A spectrometer. IR spectra were determined in KBr pellets on a Perkin-Elmer type 283

B spectrophotometer. Gas-liquid chromatograms were obtained on a Hewlett Packard type 5840 A chromatography under the conditions:

Column; 5% SE-30, size 4mm  $\times$  2m;  $\text{N}_2$ , flow rate 40ml/min, temperature; column 200°, detection 240° (FID).

Mass spectra were obtained on a Hewlett Packard GC/Mass Spectrometer (type 5985B) using a electron impact method.

**Carrageenin-Induced Edema Test**

Carrageenin-induced edema test was performed using male albino rats (Sprague Dawley strain) weighing  $170 \pm 10\text{g}$ , according to the method of Winter *et al.*<sup>5)</sup> Five or six rats per group were given compound 11 orally or *s.c.*, twice, six and one hour before the injection of 0.05ml of 1% carrageenin saline solution into the plantar surface of the right hind paw. The edema volume was measured with a plethysmometer.

**RESULTS AND DISCUSSION****Purification of (-)-Kaur-16-en-19-oic Acid [II]**

The results on screening for the isolation of active principles and on the protein stabilizing activities are summarized in Table I.

Almost all the activities in the methanol extracts of *A. continentalis* were concentrated on the ether-soluble acidic fraction. When a small portion of this fraction was methylated with diazomethane and subjected to GC/MS, it gave four major peaks as shown in Fig. 2.

Peaks 1 and 2 were turned to be methyl esters of palmitic acid and linoleic acid, respectively. The mass spectrum of peak 4 coincided with that of (-)-pimara-8(14), -15-dien-19-oic acid methyl ester, by comparing its authentic sample. Peak 3 was postulated to be methyl ester of [II] as referring to the data of literature<sup>6)</sup>.

The ether-soluble acidic fraction was chromat-

Table I: Summary of Purification of Compound-I and -II

	Total amounts (g)	Total* activity (units)	Specific* activity (units/g)	Activity yield (%)
<i>A. continentalis</i>	9,000	—	—	—
Methanol extract	1,450	$7.84 \times 10^5$	$5.1 \times 10^3$	100
Solvent fractionation				
1. ether fr.	620	$7.40 \times 10^3$	$1.19 \times 10^4$	94.4
2. butanol fr.	50	$9.45 \times 10^3$	189	0.1
3. ether-soluble acidic fr.	290	$7.28 \times 10^3$	$2.51 \times 10^4$	92.9
Silica gel chromatography				
Fr. 1	201	$5.68 \times 10^3$	$2.83 \times 10^4$	72.4
Fr. 2	14	$3.28 \times 10^5$	$2.34 \times 10^4$	4.2
Fr. 3	35	—	—	—
Crystallization from Fr. 1				
Compound I (from methanol)	6	$1.88 \times 10^5$	$3.13 \times 10^4$	2.4
Compound II (from hexane)	19	$7.31 \times 10^4$	$3.85 \times 10^4$	9.3

\* One unit of protein stabilizing activity was defined as the amount of sample required to give 50% inhibition on heat denaturation of albumin.

\*\* Protein stabilizing activity units per gram of sample.




Fig. 2. Total ion chromatogram of ether-soluble acidic fraction on a Hewlett Packard GC/Mass spectrometer (type 5985B) using an electron impact method. Scanning mass range:  $m/z$  40-600. GC conditions: OV-1 fused capillary column (0.2mm i.d.  $\times$  25m); temp. 1: 180°C, time 1: 2 min, rate: 4°C/min, temp. 2: 320°C, carrier gas: helium ( $\mu=20$ cm/sec).

ographed on a silica gel column, and separated into its 3 fractions. Fraction 1 with the majority of activity (72.4%) exhibited a single spot on TLC (Fig. 1), but did two peaks corresponding to peaks 3 and 4 by the gas chromatography of

its methyl ester. (Fig. 2)

Without any further purification of fraction 1, its methanol solution yielded compound 1. The filtrate was concentrated *in vacuo*, and the residue was dissolved in n-hexane. This n-hexane solution made easy the crystallization of compound II. And the filtrate still contained a large amount of above two compounds, which have not been completely separated each other.

Fraction 2 with a low yield except high specific activity was turned to be the mixture of palmitic acid and linoleic acid by GC of its methyl ester. Fraction 3 without activity was not further studied.

The IR and PMR spectra of [I] were coincided with those of (-)-pimara-8 (14), 15-dien-19-oic acid previously isolated<sup>1)</sup>.

Compound II was positive in Libermann-Buchard reaction and negative in Zimmermann test and nitrogen test. Its IR spectrum showed the presences of carboxylic acid (3000~2500, 1685  $\text{cm}^{-1}$ ) and a disubstituted vinyl group (3060, 1650, 875  $\text{cm}^{-1}$ ). [II] afforded its methyl ester,

of which IR spectrum showed an absorption band at  $1725\text{cm}^{-1}$  (ester) and did not at  $4000\sim 3100\text{cm}^{-1}$ , revealing the absence of ketone and hydroxyl groups. The mass spectrum of [II] showed the molecular ion at  $m/z$  302, giving a possible molecular formula  $\text{C}_{20}\text{H}_{30}\text{O}_2$ . Proton NMR of [II] exhibited the presences of a carboxylic acid (11.4 ppm, 1H, diffused), a disubstituted vinyl group (4.74ppm, 2H, d-like), and two angular methyls (0.95, 1.24ppm,  $2\times 3\text{H}$ , s), which were also supported by PMR of its methyl ester; a carboxy methyl ester (3.62 ppm, s) and some up-field shifts of a vinyl group (4.62 ppm) and two methyl signals (0.85, 1.18 ppm).

The patterns of proton NMR of [II] and its methyl ester, and other spectral data mentioned above are identical with those of (–)-kaur-16-en-19-oic acid and its methyl ester, respectively, which were already isolated from *A. cordata*<sup>3)</sup> and *Xylopia aethiopica*.<sup>6)</sup>

The  $^{13}\text{C}$ -NMR spectra provided conclusive assignment for the structure of [II]. Application of attached proton test of [II] yielded the data described in "EXPERIMENTAL METHODS", which were coincided with those of (–)-kaur-16-en-19-oic acid.<sup>6)</sup>

#### The Contents of [I] and [II]

The contents of [I] and [II] were determined 0.9 and 2.1%, respectively, in the roots of the plant by GLC technique after methylation of its ether-soluble acidic fraction. The roots were finely powdered before methanol extraction (three times). Both methyl esters of [I] and [II] were each other used as internal references.

#### The Protein Stabilizing Activity of [II]

To determine the protein stabilizing activity of [II], dose-response curves were drawn as shown in Fig. 3, by plotting values for the inhibition rates of serial dilutions of [II], together with [I] and phenylbutazone as references.




Fig. 3. Protein stabilizing potency of (–)-kaur-16-en-19-oic acid.

- a : (–)-kaur-16-en-19-oic acid
- b : (–)-pimara-8(14), 15-dien-19-oic acid
- c : phenylbutazone

$\text{IC}_{50}$  of [II], [I], and phenylbutazone are 0.026, 0.032, and 0.32 mg/3ml, respectively.

The protein stabilizing activity of [II] is more potent to some extent than that of [I], and approximately twelve times more than that of phenylbutazone. The  $\text{IC}_{50}$  value of [I] is lower than the data described in our previous paper (0.115 mg/3ml). This was found to be an error due to its poor solubility in the buffer. In this study, the samples were thoroughly dissolved in 0.3M NaOH, neutralized to pH 8 to 9 with 0.3M HCl, and then serial dilutions were made with buffered saline (pH 5.3)

#### The Anti-inflammatory Activity of [II]

The anti-inflammatory effect of [II], 3, 10 and 30 mg/kg, *s.c.*; 33 and 100 mg/kg, *p.o.*, on carrageenin-induced edema in rat hind paw were investigated, and the results were compared with those of phenylbutazone, 30 mg/kg, *s.c.* and 100 mg/kg, *p.o.*, respectively, as shown in Table II and III.

On *s.c.* administration, [II], 10 and 30 mg/kg, and phenylbutazone, 30 mg/kg, suppressed significantly the edema volumes by 41.5, 48.2 and 57.6% on average 3.5 hr after the treatment with carrageenin, respectively. This sugge-

**Table II: Anti-inflammatory activity of (-)-kaur-16-en-19-oic acid administered s.c.**

Compound	Dose mg/kg s.c.	No. of animals	Edema increased per cent (Inhibition percent)				
			0.5 hr	1.5 hr	2.5 hr	3.5 hr	4.5 hr
Control	% CMC-Na	5	13.67±3.70	35.96±5.60	55.6±4.86	60.04±3.79	45.77±4.08
Phenylbutazone	30	5	4.93±2.26	14.18±1.29**	18.00±2.79** (67.6)	25.44±5.67** (57.6)	19.43±3.29**
[II]	30	5	3.43±0.97**	13.51±6.00*	21.35±5.01** (61.6)	31.11±4.11*** (48.2)	25.63±2.17**
[II]	10	5	15.35±4.80	23.45±3.17	34.00±6.05* (38.8)	35.15±4.65** (41.5)	23.09±2.51**
[II]	3	5	12.41±1.95	14.77±4.07*	33.23±6.01* (40.2)	42.32±7.30 (29.5)	26.18±6.56*

\*p<0.05 \*\*p<0.01 \*\*\*p<0.001 when compared with control.

**Table III: Anti-inflammatory activity of (-)-kaur-16-en-19-oic acid administered p.o.**

Compound	Dose mg/kg p.o.	No. of animals	Edema increased percent (inhibition per cent)				
			0.5 hr	1.5 hr	2.5 hr	3.5 hr	4.5 hr
Control	1% CMC-Na	5	16.78±4.78	26.64±5.90	55.18±7.33	60.91±7.44	43.14±6.05
Phenylbutazone	100	5	7.55±2.03	15.80±1.92*	19.45±3.08** (64.8)	31.26±5.50* (48.7)	30.11±10.43
II	100	5	5.27±1.62	10.62±3.04	18.12±5.51* (67.2)	26.04±5.45* (57.2)	16.94±5.11
II	33	5	7.86±0.91**	17.53±5.97	21.89±8.09** (60.3)	30.58±6.67** (49.8)	25.87±4.80*

\*p<0.05 \*\*p<0.01 when compared with control.

sted that [II] administered s.c. showed a lower anti-inflammatory activity than phenylbutazone.

When administered p.o., [II], 33 and 100 mg/kg, and phenylbutazone, 100 mg/kg, caused the significant inhibitions of 49.8, 57.2 and 48.7% on average 3.5 hour after the carrageenin treatment, respectively. By a rough estimation, [II] administered p.o. shows an anti-inflammatory activity of over three times of phenylbutazone. These results indicate that the p.o. administration of [II] is more effective. In contrast to [II], [I] previously reported was more active in case of the s.c. administration.

In conclusion, it can be summarized that [II] as well as [I] is a non-steroidal anti-inflammatory component, both involving the majority of activities of *A. continentalis*. And it is noteworthy

that the anti-inflammatory components isolated from natural resources showed more potent actions than phenylbutazone used clinically.

### LITERATURE CITED

- 1) Han, B.H., Han, Y.N., Han, K.A., Park, M.H., and Lee, E.O.: Studies on the anti-inflammatory activity of *Aralia continentalis* (I). Characterization of continentalic acid and its anti-inflammatory activity, *Arch. Pharm. Res.*, 6, 17(1983).
- 2) Mizushima, Y.: *Lancet* 1, 169 (1965); *ibid.* 2, 443 (1966).
- 3) Shibata, S., Mihashi, S., and Tanaka, O.: The occurrence of (-)-pimarane-type diterpene in *Aralia cordata* Thunb. *Tetrahedron Letters* No. 51, 5241 (1967).
- 4) Tanaka, O., Yasuda, Y., Yamaski, K., and Mih-

- ashi, S.: Comparative study on the constituents of some Aralia species and notice of the original plants of crude drug "Duhuo", *Yakugaku Zasshi* **92**, 1058 (1972).
- 5) Winter, C.A., Risley, E.A., and Nuss, G.W.: Anti-inflammatory and antipyretic activities of indomethacin. *J. Pharmacol. Exptl. Therap.* **141**, 369 (1963).
- 6) Hasan, C.M., Healey, T.M., Waterman, P.G.: Kolavane and Kaurane diterpenes from the stem bark of *Xylopi aethiopica*, *Phytochem.* **21**, 1365 (1982).